Talphera (TLPH) Retained Earnings (2010 - 2026)
Talphera's (TLPH) quarterly Retained Earnings came in at $492.5 million in Q1 2026, up 207.11% year-on-year from $160.4 million in Q1 2025, and up 0.82% quarter-over-quarter from $488.5 million in Q4 2025.
Talphera (TLPH) Retained Earnings (2010 - 2026) Analysis & Trends
Talphera's Retained Earnings history runs 17 years deep, the most recent figure standing at $492.5 million for Q1 2026.
- On a quarterly basis, Retained Earnings rose 207.11% year-over-year to $492.5 million in Q1 2026; TTM through Mar 2026 was $492.5 million, a 207.11% increase from a year earlier, with the FY2025 full-year figure at $488.5 million, up 206.84% from the prior year.
- Retained Earnings rose to $492.5 million in Q1 2026 per TLPH's latest filing, from $488.5 million in the prior quarter.
- Across five years, Retained Earnings topped out at $492.5 million in Q1 2026 and bottomed at -$482.3 million in Q1 2022.
- The 5-year median for Retained Earnings is $448.2 million (2023), against an average of $91.0 million.
- Across the five-year window, Retained Earnings slumped 214.82% in 2022 and jumped 207.63% in 2023, its largest moves.
- Year by year, Retained Earnings stood at -$425.8 million in 2022, then soared by 207.63% to $458.3 million in 2023, then plunged by 199.76% to -$457.2 million in 2024, then jumped by 206.84% to $488.5 million in 2025, then gained by 0.82% to $492.5 million in 2026.
- Per Business Quant, the three latest TLPH Retained Earnings figures stand at $492.5 million (Q1 2026), $488.5 million (Q4 2025), and $486.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | 492.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 492.50 Mn |
| Dec 31, 2025 | 488.51 Mn |
| Sep 30, 2025 | 486.88 Mn |
| Jun 30, 2025 | 469.92 Mn |
| Mar 31, 2025 | -459.82 Mn |
| Dec 31, 2024 | -457.23 Mn |
| Sep 30, 2024 | -455.36 Mn |
| Jun 30, 2024 | 464.72 Mn |
| Mar 31, 2024 | 464.50 Mn |
| Dec 31, 2023 | 458.31 Mn |
| Sep 30, 2023 | 458.00 Mn |
| Jun 30, 2023 | -438.35 Mn |
| Mar 31, 2023 | 448.21 Mn |
| Dec 31, 2022 | -425.83 Mn |
| Sep 30, 2022 | 445.56 Mn |
| Jun 30, 2022 | -411.60 Mn |
| Mar 31, 2022 | -482.26 Mn |
| Dec 31, 2021 | 437.68 Mn |
| Sep 30, 2021 | -465.67 Mn |
| Jun 30, 2021 | -457.29 Mn |